ProBio Strengthens Leadership Team With Key Appointments

ProBio, a leading CDMO company, has named new leaders to strengthen its mission of advancing life-changing therapies. Effective December 1, 2024, Allen Guo will take over as CEO, Whitney Winters will become Senior Vice President of U.S. Business Development, and Michael Vreeland will serve as the U.S. Site Head and Interim Head of U.S. Process Development. These appointments aim to support ProBio's commitment to helping patients by accelerating biotech and pharmaceutical innovations.

Allen Guo, who joined ProBio in 2021, brings 16 years of experience from companies like Janssen, Lonza, Becton Dickinson, and Patheon. He has played a key role in ProBio’s growth by leading a business development team that supports clients from discovery to the pre-commercial BLA stage across various modalities. His efforts have driven major projects, boosted revenue, and built strong, high-performing teams.

Li Zhu, Chairman of the Board of Directors of ProBio, said in a statement, "Allen, Whitney, and Michael are uniquely qualified to lead ProBio into its next phase of growth. Their expertise and commitment to innovation and collaboration will ensure ProBio continues to empower our customers in delivering therapies that transform patients' lives.”

Allen Guo, incoming CEO of ProBio, commented, "It is an honour to take on this role and continue to contribute to ProBio's mission. Together with our talented team, I am committed to driving innovation, delivering quality solutions, and empowering our customers to develop therapies that make a lasting impact on patients' lives.”

Whitney Winters joined ProBio this year as Vice President of Commercial Excellence, bringing 17 years of experience in sales and marketing, including her time at West Pharmaceutical Services. With a strong background in strategy and execution, she will now oversee business development and marketing at ProBio, aligning commercial strategies for growth. Her leadership has already strengthened ProBio’s vision of supporting transformative therapies and will play a key role in expanding the company’s presence in the U.S. market.

Whitney Winters, incoming SVP of U.S. Business Development, also stated, "I am thrilled to take on this role at such an exciting time for ProBio. With our cutting-edge CDMO capabilities, I look forward to expanding our U.S. presence and collaborating with our customers to bring transformative therapies to patients around the world.”

Michael Vreeland has joined ProBio as the U.S. Site Head and Interim Head of Process Development, leading operations at the cutting-edge manufacturing facility in Hopewell, New Jersey. This facility is ProBio’s North American hub for plasmid DNA and viral vector production. With over 16 years of cGMP manufacturing experience from companies like Curia, Thermo Fisher Scientific, and Sanofi Pasteur, Michael brings extensive expertise in biologics manufacturing, process development, and advanced therapies. Dr. Li Chen, ProBio’s former CEO, will continue supporting the company as a consultant to ensure a smooth leadership transition and continued progress.

Michael Vreeland, US Site Head and Interim Head of Process Development, further added, "I am excited to lead ProBio's U.S. manufacturing operations and help deliver high-quality solutions that support our customers in advancing life-changing therapies. Together, we will drive operational excellence and continue to fulfil ProBio's mission of improving patient outcomes.”

Founded in 2020, ProBio is a trusted global CDMO specializing in tailored solutions for biologics and advanced therapies. Having supported over 108 IND clearances worldwide, ProBio is committed to helping biopharma companies bring transformative therapies to patients. These leadership appointments further enhance ProBio’s focus on innovation, customer-centricity, and advancing healthcare for a better future.